Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics is generating immense potential in the biotech industry with their innovative TANGO platform and drug candidates such as zorevunersen and STK-002. These drugs have shown promising results in preclinical and early clinical trials in treating genetic diseases, and the company's partnerships with other biotech companies further solidify their position in the market. With a strong cash position and a potential for disease modification, Stoke has the capability to address a broad unmet need in the genetic disease space.

Bears say

Stoke Therapeutics is facing potential challenges in successfully developing and commercializing its RNA medicine approach, with limited data from its early programs. Its financial results show a significant increase in expenses, with continued reliance on third-party data and the need for additional capital to become profitable. The company also faces risks related to potential patent disputes and the volatility of its stock price due to a significant stake held by Skorpios Trust. Adherence to appropriate pricing strategies will be crucial in ensuring market acceptance for its product candidates and maintaining adequate coverage and reimbursement.

STOK has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 10 analysts, STOK has a Strong Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.